Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs

Pulmonary Pharmacology and Therapeutics

Volumn 11, Issue 1, 1998, Pages 13-21

  Dent, G ^a,c   Poppe, H ^b   Egerland, J ^b   Marx, D ^b   Szelenyi, I ^b   Branscheid, D ^a   Magnussen, H ^a   Rabe, K F ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Arzneimittelwerk Dresden GmbH   (Germany)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Airways smooth muscle; Allergic eosinophilia; Eosinophils; PDE4; Phosphodiesterase inhibitors

Indexed keywords

1 ETHYL 8 METHOXY 3 METHYL 5 PROPYL IMIDAZO[1,5 A]PYRIDO[3,2 E] PYRAZINONE; ALLERGEN; D 22888; DEXAMETHASONE; PHOSPHODIESTERASE INHIBITOR; SUPEROXIDE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHODILATATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; EOSINOPHIL; GUINEA PIG; HUMAN; HUMAN CELL; HUMAN TISSUE; LOEFFLER PNEUMONIA; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY BURST; SMOOTH MUSCLE TONE;

EID: 0032004153     PISSN: 10945539     EISSN: None     Source Type: Journal    
DOI: 10.1006/pupt.1998.0111     Document Type: Article

References (41)

1. 1. Kay A B. Eosinophils as effector cells in immunity and hypersensitivity disorders. Clin Exp Immunol 1985; 62: 1-12.
2. 2. Barnes P J. Our changing understanding of asthma. Respir Med 1989; 83 (Suppl. A): 17-22.
3. 3. Corrigan C J, Kay A B. T cells and eosinophils in the pathogenesis of asthma. Immunol Today 1992; 13: 501-507.
4. 4. Bousquet J, Chanez P, Lacoste J Y, Barneon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony Lafontaine J, Godard P, Michel F B. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033-1039.
5. 5. Gulbenkian A R, Fernandez X, Kreutner W, Minnicozzi M, Watnick A S, Kung T, Egan R W. Anaphylactic challenge causes eosinophil accumulation in bronchoalveolar lavage fluid of guinea pigs: modulation by betamethasone, phenidone, indomethacin, WEB 2086 and a novel antiallergy agent, SCH 37224. Am Rev Respir Dis 1990; 142: 680-685.
6. 6. Chand N, Harrison J E, Rooney S M, Nolan K W, De Vine C L, Jakubicki R G, Pillar J, Diamantis W, Sofia R D. Allergic bronchial eosinophilia: a therapeutic approach for the selection of potential bronchial anti-inflammatory drugs. Allergy 1993; 48: 624-626.
7. 7. Santing R E, Olymulder C G, Zaagsma J, Meurs H. Relationships among allergen-induced early and late phase airway obstructions, bronchial hyperreactivity, and inflammation in conscious, unrestrained guinea pigs. J Allergy Clin Immunol 1994; 93: 1021-1030.
8. 8. Dent G, Giembycz M A. Selective phosphodiesterase inhibitors in the therapy of asthma. Clin Immunother 1995; 3: 423-437.
9. 9. Szelenyi I, Poppe H, Dent G, Magnussen H, Rabe K F. Effects of a selective PDE4 inhibitor, D22888, on human airways and eosinophils in vitro and late phase allergic eosinophilia in guinea pigs. Am J Respir Crit Care Med 1997; 155: A624. (Abstract)
10. 10. Poppe H, Marx D, Egerland U, Höfgen N, Szelenyi I. The effects of selective type 4 phosphodiesterase (PDE)-inhibitors on late phase eosinophilia in actively sensitized guinea-pigs after single and repeated pre-treatment. Eur Respir J 1997; 10 (Suppl. 25): S312. (Abstract)
11. 11. Rabe K F, Tenor H, Dent G, Schudt C, Liebig S, Magnussen H. Phosphodiesterase isoenzymes modulating inherent tone in human airways: identification and characterization. Am J Physiol 1993; 264: L458-L464.
12. 12. Rabe K F, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and the effect of selective PDE inhibitors. Am J Physiol 1994; 266: L536-L543.
13. 13. Dent G, Muñoz N M, Rühlmann E, Zhu X, Leff A R, Magnussen H, Rabe K F. Protein kinase C inhibition enhances platelet activating factor-induced eicosanoid production in human eosinophils. Am J Respir Cell Mol Biol 1998; 18: 136-144.
14. 14. Dent G, Giembycz M A, Evans P M, Rabe K F, Barnes P J. Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J Pharmacol Exp Ther 1994; 271: 1167-1174.
15. 15. Böyum A. Isolation of mononuclear cells and granulocytes from human blood: isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 1968; Suppl. 97: 77-89.
16. 16. Thompson W J, Appleman M M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971; 10: 311-316.
17. 17. Dent G, Giembycz M A, Rabe K F, Barnes P J. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors. Br J Pharmacol 1991; 103: 1339-1346.
18. 18. Rabe K F, Dent G. Theophylline. In: Barnes P J, Grunstein M M, Leff A R, Woolcock A J eds. Asthma. Philadelphia: Lippincott-Raven, 1997: 1535-1554.
19. 19. Belvisi M G, Miura M, Peters M J, Ward J K, Tadjkarimi S, Yacoub M H, Giembycz M A, Barnes P J. Effect of isoenzyme-selective cyclic nucleotide phosphodiesterase inhibitors on human tracheal smooth muscle tone. Br J Pharmacol 1992; 107: 53. (Abstract)
20. 20. Nielson C P, Vestal R E, Sturm R J, Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol 1990; 86: 801-808.
21. 21. Rabe K F, Magnussen H, Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. Eur Respir J 1995; 8: 637-642.
22. 22. Cortijo J, Bou J, Beleta J, Cardelús I, Llenas J, Morcillo E, Gristwood R W. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 1993; 108: 562-568.
23. 23. Torphy T J, Undem B J, Cieslinski L B, Luttmann M A, Reeves M L, Hay DWP. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 1993; 265: 1213-1223.
24. 24. Rabe K F, Dent G, Magnussen H. Theophylline in the treatment of bronchial asthma and chronic obstructive pulmonary disease. In: Leff A R ed. Pulmonary and critical care pharmacology and therapeutics. New York: McGraw-Hill, 1996: 525-534.
25. 25. Banner K H, Page C P. Theophylline and selective phosphodiesterase inhibitors as anti-inflammatory drugs in the treatment of bronchial asthma. Eur Respir J 1995; 8: 996-1000.
26. 26. Souness J E, Carter C M, Diocee B K, Hassall G A, Wood L J, Turner N C. Characterization of guinea-pig eosinophil phosphodiesterase activity: assessment of its involvement in regulating superoxide generation. Biochem Pharmacol 1991; 42: 937-945.
27. 27. Banner K H, Moriggi E, Da Ros B, Schioppacassi G, Semeraro G, Page C P. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996; 119: 1255-1261.
28. 4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol 1996; 118: 1727-1735.
29. 29. Sanjar S, Aoki S, Kristersson A, Smith D, Morley J. Antigen challenge induces pulmonary airway eosinophil accumulation and airway hyperreactivity in sensitized guinea-pigs: the effect of anti-asthma drugs. Br J Pharmacol 1990; 99: 679-686.
30. 30. Underwood D C, Osborn R R, Novak L B, Matthews J K, Newsholme S J, Undem B J, Hand J M, Torphy T J. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea-pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram. J Pharmacol Exp Ther 1993; 266: 306-313.
31. 31. Elwood W, Sun J, Barnes P J, Giembycz M A, Chung K F. Inhibition of allergen-induced lung eosinophilia by type IV and combined type III and IV-selective phosphodiesterase inhibitors in brown-Norway rats. Inflamm Res 1995; 44: 83-86.
32. 32. Gozzard N, Herd C M, Blake S M, Holbrook M, Hughes B, Higgs G A, Page C P. Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits. Br J Pharmacol 1996; 117: 1405-1412.
33. 33. Tarayre J P, Aliaga M, Barbara M, Malfetes N, Vieu S, Tisne-Versailles J. Theophylline reduces pulmonary eosinophilia after various types of active anaphylactic shock in guinea-pigs. J Pharm Pharmacol 1991; 43: 877-879.
34. 34. Souness J E. Characterization of different states of PDE4 by rolipram and RP 73401. In: Schudt C, Dent G, Rabe K F eds. Phosphodiesterase inhibitors. London: Academic Press, 1996: 173-184.
35. 35. Naline E, Qian Y, Advenier C, Raeburn D, Karlsson J-A. Effects of RP 73401, a novel, potent and selective phosphodiesterase type 4 inhibitor, on contractility of human, isolated bronchial muscle. Br J Pharmacol 1996; 118: 1939-1944.
36. 36. Souness J E, Maslen C, Webber S, Foster M, Raeburn D, Palfreyman M N, Ashton M J, Karlsson J-A. Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipram. Br J Pharmacol 1995; 114: 39-46.
37. 37. Hatzelmann A, Tenor H, Schudt C. Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br J Pharmacol 1995; 114: 821-831.
38. 38. Torphy T J. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 1998; 157: 351-370.
39. 39. Harbinson P L, MacLeod D, Hawksworth R, O'Toole S, Sullivan P J, Heath P, Kilfeather S, Page C P, Costello J, Holgate S T, Lee T H. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J 1997; 10: 1008-1014.
40. 40. Horowski R, Sastre-Y-Hernandez M. Clinical effects of the neurotropic selective cAMP phosphodiesterase inhibitor rolipram in depressed patients: global evaluation of the preliminary reports. Curr Ther Res 1985; 38: 23-29.
41. 41. Nieman R B, Fisher B D, Amit O, Dockhorn R J. SB 207499 (Ariflo™), a second generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am J Respir Crit Care Med 1998; 157: A413. (Abstract)